[go: up one dir, main page]

MX2009008170A - Nuevos biomateriales para la distribucion de farmaco ocular y metodo para hacerlos y utilizarlos. - Google Patents

Nuevos biomateriales para la distribucion de farmaco ocular y metodo para hacerlos y utilizarlos.

Info

Publication number
MX2009008170A
MX2009008170A MX2009008170A MX2009008170A MX2009008170A MX 2009008170 A MX2009008170 A MX 2009008170A MX 2009008170 A MX2009008170 A MX 2009008170A MX 2009008170 A MX2009008170 A MX 2009008170A MX 2009008170 A MX2009008170 A MX 2009008170A
Authority
MX
Mexico
Prior art keywords
drug delivery
making
same
ocular drug
novel biomaterials
Prior art date
Application number
MX2009008170A
Other languages
English (en)
Inventor
James N Chang
Ronald E Utecht
Kaia L Kloster
Therese M Downey
Barbara R Haberer
Patrick D Youso
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2009008170A publication Critical patent/MX2009008170A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Birds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se describe un nuevo biomaterial que propiedades únicas que lo hacen útil en las aplicaciones de distribución de fármaco ocular en donde los fármacos se seleccionan del grupo que consiste de una prostaglandina, una prostamida, un fármaco antiinflamatorio no esteroide (NSAID) , y un corticoesteroide, y sus mezclas, derivados, sales y ésteres.
MX2009008170A 2007-01-31 2008-01-31 Nuevos biomateriales para la distribucion de farmaco ocular y metodo para hacerlos y utilizarlos. MX2009008170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88755907P 2007-01-31 2007-01-31
PCT/US2008/001301 WO2008094659A2 (en) 2007-01-31 2008-01-31 Novel biomaterials for ocular drug delivery and a method for making and using same

Publications (1)

Publication Number Publication Date
MX2009008170A true MX2009008170A (es) 2009-08-12

Family

ID=39409833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008170A MX2009008170A (es) 2007-01-31 2008-01-31 Nuevos biomateriales para la distribucion de farmaco ocular y metodo para hacerlos y utilizarlos.

Country Status (9)

Country Link
US (5) US8252771B2 (es)
EP (2) EP2425816A3 (es)
JP (2) JP5541926B2 (es)
KR (1) KR20090108723A (es)
AU (1) AU2008211083B2 (es)
BR (1) BRPI0807065A2 (es)
CA (1) CA2676919C (es)
MX (1) MX2009008170A (es)
WO (2) WO2008094675A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119780B2 (en) 2006-06-02 2012-02-21 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
US20080248508A1 (en) * 2006-08-17 2008-10-09 Shenda Baker Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials
MX2009008170A (es) * 2007-01-31 2009-08-12 Allergan Inc Nuevos biomateriales para la distribucion de farmaco ocular y metodo para hacerlos y utilizarlos.
US8871247B2 (en) 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
US20100009009A1 (en) * 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
CN101780105B (zh) * 2009-01-20 2011-09-28 沈阳兴齐制药有限公司 小牛血去蛋白提取物的滴眼液
US20100233101A1 (en) 2009-02-13 2010-09-16 Micropure, Inc. Composition and method for the oxidative consumption of salivary biomolecules
EP2477617B1 (en) * 2009-09-18 2018-01-31 Bioinspire Technologies Inc. Free-standing biodegradable patch
US9271925B2 (en) 2013-03-11 2016-03-01 Bioinspire Technologies, Inc. Multi-layer biodegradable device having adjustable drug release profile
CN101695583B (zh) * 2009-10-29 2012-12-26 中国人民解放军第三军医大学第一附属医院 一种用于组织修复的颗粒状生物材料及其制备方法
WO2011130646A1 (en) 2010-04-15 2011-10-20 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
AU2011323078B2 (en) * 2010-11-06 2016-04-14 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery
BR112013020719B1 (pt) 2011-02-14 2018-04-17 Allergan, Inc. Composições de derivados de bimatoprost tipo éster e métodos
JP6144254B2 (ja) 2011-04-15 2017-06-07 マリン ポリマー テクノロジーズ，インコーポレーテッド ポリ−ｎ−アセチルグルコサミンナノファイバを用いた疾患の治療
US9962401B2 (en) * 2011-09-27 2018-05-08 Purdue Research Foundation Chitosan derivatives for inactivation of endotoxins and surface protection of nanoparticles
KR20140103099A (ko) * 2011-10-12 2014-08-25 아센디스 파마 옵탈몰로지 디비젼 에이/에스 안구 병태의 예방 및 치료
US8968790B2 (en) * 2011-12-09 2015-03-03 Shaker A. Mousa Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
US9956291B2 (en) * 2012-07-10 2018-05-01 Shaker A. Mousa Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting
CA2891949C (en) * 2012-12-07 2021-03-23 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
TWI485189B (zh) 2012-12-28 2015-05-21 Ind Tech Res Inst 固體製劑及其製造方法
WO2014152796A2 (en) 2013-03-14 2014-09-25 Hemcon Medical Technologies, Inc. Biocompatible and bioabsorbable derivatized chitosan compositions
GB201309788D0 (en) * 2013-05-31 2013-07-17 Medtrade Products Ltd Process for the removal of contamination from a raw material
AU2015257874B2 (en) 2014-05-07 2019-11-28 Croma-Pharma Gesellschaft M.B.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
US10449272B2 (en) 2015-10-16 2019-10-22 Industrial Technology Research Institute Hydrogel composition and method for using the same
RU2018119674A (ru) 2015-10-30 2019-12-02 Крома-Фарма Гезелльшафт М.Б.Х. Применение в терапии стерильного водного офтальмологического раствора
ES2796361T3 (es) 2015-10-30 2020-11-26 Croma Pharma Gmbh Uso terapéutico de una solución oftálmica acuosa estéril
WO2017116908A1 (en) * 2015-12-28 2017-07-06 Alumend, Llc Compositions and methods to affect skin irritation
ES2934790T3 (es) 2016-08-19 2023-02-27 Orasis Pharmaceuticals Ltd Composiciones farmacéuticas oftálmicas y usos que se relacionan con las mismas
CA3020197C (en) 2017-09-01 2024-06-04 Micropure, Inc. Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions
CN110343263A (zh) * 2018-04-02 2019-10-18 中国海洋大学 一种基于氢氧化钾和低温溶解壳聚糖的方法
WO2020146353A1 (en) 2019-01-08 2020-07-16 Alumend, Llc Topical compositions containing low molecular weight chitosan derivatives
WO2021019562A2 (en) 2019-07-26 2021-02-04 Pandorum Technologies Private Limited Bioengineered formulation, process for preparing and implementations thereof
KR102119693B1 (ko) * 2019-10-31 2020-06-05 경희대학교 산학협력단 숙신화 콜라겐-피브리노겐 하이드로겔의 제조방법
WO2021203045A1 (en) * 2020-04-03 2021-10-07 Tissuetech, Inc. Methods of using umbilical cord products for treatment of ocular surface disorders
JP2024508811A (ja) 2021-02-24 2024-02-28 オキュラ セラピューティクス，インコーポレイテッド 小管内デポーインサータ装置
CN113440643B (zh) * 2021-06-10 2022-04-29 武汉大学 一种可吸收外科材料的表面抗菌处理方法
CN113881070B (zh) * 2021-11-09 2022-11-15 中北大学 具有光-应力双重响应的碳量子点/壳聚糖衍生物水凝胶的制备方法及应用
WO2025090805A1 (en) * 2023-10-25 2025-05-01 The Board Of Trustees Of The Leland Stanford Junior University Antimicrobial irrigation solutions for endourological procedures

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69101710T2 (de) * 1990-07-26 1994-08-18 G.D. Searle & Co., Chicago, Ill. Arzneimittel freisetzendes polymeres system.
FR2707878A1 (fr) * 1993-07-21 1995-01-27 Imedex Nouvelles compositions adhésives à usage chirurgical.
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
TW389694B (en) * 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
US6015474A (en) 1997-06-20 2000-01-18 Protein Polymer Technologies Methods of using primer molecules for enhancing the mechanical performance of tissue adhesives and sealants
US6200595B1 (en) 1998-04-24 2001-03-13 Kuraray Co., Ltd. Medical adhesive
JP2000288079A (ja) 1999-04-07 2000-10-17 Toyobo Co Ltd 生体組織用接着剤
WO2001000246A2 (en) * 1999-06-11 2001-01-04 Shearwater Corporation Hydrogels derived from chitosan and poly(ethylene glycol)
US6310188B1 (en) * 2000-01-24 2001-10-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for producing chitin or chitosan
US6991652B2 (en) * 2000-06-13 2006-01-31 Burg Karen J L Tissue engineering composite
US20040047892A1 (en) * 2000-11-15 2004-03-11 Desrosiers Eric Andre Filler composition for soft tissue augmentation and reconstructive surgery
US6756363B1 (en) * 2000-11-17 2004-06-29 Wound Healing Of Oklahoma, Inc. Solutions and films of glycated chitosan
KR100507968B1 (ko) * 2001-08-18 2005-08-17 한국과학기술연구원 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법
ATA13842001A (de) * 2001-08-31 2002-10-15 Mucobiomer Biotechnologische F Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung
CA2586320A1 (en) 2003-11-05 2005-05-19 Photobiomed Corporation Bonding tissues and cross-linking proteins with naphthalimide compounds
EP1753787B1 (en) 2004-05-20 2016-10-19 Mentor Worldwide LLC Method of covalently linking hyaluronan and chitosan
US20050283004A1 (en) * 2004-06-18 2005-12-22 Hopax Chemicals Manufacturing Co., Ltd. Alkylsulfonated polyaminosaccharides
KR100578382B1 (ko) * 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
CA2586074C (en) * 2004-11-09 2013-07-23 Novagali Pharma Sa Ophthalmic oil-in-water type emulsion with stable positive zeta potential
GB0615834D0 (en) * 2006-08-09 2006-09-20 Univ Glasgow Polymeric micellar clusters and their uses in formulating drugs
MX2009008170A (es) * 2007-01-31 2009-08-12 Allergan Inc Nuevos biomateriales para la distribucion de farmaco ocular y metodo para hacerlos y utilizarlos.

Also Published As

Publication number Publication date
WO2008094659A3 (en) 2009-05-14
EP2425816A3 (en) 2014-04-30
CA2676919A1 (en) 2008-08-07
US9855337B2 (en) 2018-01-02
JP2010516814A (ja) 2010-05-20
CA2676919C (en) 2013-01-29
BRPI0807065A2 (pt) 2017-03-21
US8252771B2 (en) 2012-08-28
JP2014129408A (ja) 2014-07-10
EP2114370B1 (en) 2012-10-03
WO2008094659A2 (en) 2008-08-07
US20080207561A1 (en) 2008-08-28
US20180344858A1 (en) 2018-12-06
US20080200948A1 (en) 2008-08-21
US9884121B2 (en) 2018-02-06
AU2008211083B2 (en) 2013-08-01
EP2114370A2 (en) 2009-11-11
US20160175449A1 (en) 2016-06-23
JP5541926B2 (ja) 2014-07-09
AU2008211083A1 (en) 2008-08-07
WO2008094675A2 (en) 2008-08-07
KR20090108723A (ko) 2009-10-16
US20180344859A1 (en) 2018-12-06
WO2008094675A3 (en) 2009-11-26
EP2425816A2 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
MX2009008170A (es) Nuevos biomateriales para la distribucion de farmaco ocular y metodo para hacerlos y utilizarlos.
CY1122687T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο
EP4364795A3 (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
WO2012056111A3 (en) Drug delivery compositions
WO2010078486A3 (en) Opioid-containing oral pharmaceutical compositions and methods
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
BR112012030818A2 (pt) "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CY1109606T1 (el) Βιοδιασπωμενο υμενιο για την απελευθερωση φαρμακου στον οφθαλμο
SG170087A1 (en) Pharmaceutical compositions
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
BRPI0812064A2 (pt) Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
CL2007003264A1 (es) Compuestos derivados de 1,4-benzotiepina 1,1-dioxido sustituidos con radicales bencilo; producto farmaceutico; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del sn
WO2008000731A3 (en) Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
CL2007003263A1 (es) Compuestos derivados de 1,4-benzotiepina 1,1-dioxido; producto farmaceutico; procedimiento de preparacion; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, e
WO2009111611A3 (en) Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
CY1111954T1 (el) Παραγωγα τετραϋδροναφθαλινιου, μεθοδοι για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδη
CY1108231T1 (el) Σταθερη στερεα δοσολογικη μορφη περιλαμβανουσα δεσμοπρεσσινη
CY1113551T1 (el) Υποκατεστημενες ενωσεις νικοτιναμιδιου και η χρησιμοποιηση τους σε φαρμακα
WO2008101173A3 (en) Biodegradable compositions and materials
NO20080035L (no) Benzooksazol-2-on derivater som lipase og fosfolipaseinhibitorer
WO2009116078A3 (en) Oral dosage form containing a pyridinol derivative
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer

Legal Events

Date Code Title Description
FG Grant or registration